Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik Ames

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
International Review of Cell and Molecular Biology|July 7, 2022
Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatmentCordelia Dunai, Erik Ames, Maria C Ochoa, et al.
Blood|December 21, 2011
Mouse NK cell-mediated rejection of bone marrow allografts exhibits patterns consistent with Ly49 subset licensingKai Sun, Maite Alvarez, Erik Ames, et al.
Transplantation|April 8, 2014
Natural killer cell subsets differentially reject embryonic stem cells based on licensingJessica Perez-Cunningham, Erik Ames, Rachel C Smith, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 23, 2008
Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responsesWilliam H D Hallett, Erik Ames, Maite Álvarez, et al.
Oncoimmunology|September 26, 2015
Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cellsErik Ames, Robert J Canter, Steven K Grossenbacher, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 17, 2013
Murine natural killer cell licensing and regulation by T regulatory cells in viral responsesCan M Sungur, Yajarayma J Tang-Feldman, Erik Ames, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2007
Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibitionWilliam H D Hallett, Erik Ames, Milad Motarjemi, et al.
Cancers|January 17, 2019
Bortezomib Augments Natural Killer Cell Targeting of Stem-Like Tumor CellsJesus I Luna, Steven K Grossenbacher, Ian R Sturgill, et al.
Blood|April 19, 2011
Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHCIsabel Barao, Maite Alvarez, Erik Ames, et al.
Blood|July 11, 2014
Treatment of chronic graft-versus-host disease with bortezomibChien-Chun Steven Pai, Mingyi Chen, Annie Mirsoian, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
International Review of Cell and Molecular Biology|July 7, 2022
Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatmentCordelia Dunai, Erik Ames, Maria C Ochoa, et al.
Blood|December 21, 2011
Mouse NK cell-mediated rejection of bone marrow allografts exhibits patterns consistent with Ly49 subset licensingKai Sun, Maite Alvarez, Erik Ames, et al.
Transplantation|April 8, 2014
Natural killer cell subsets differentially reject embryonic stem cells based on licensingJessica Perez-Cunningham, Erik Ames, Rachel C Smith, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 23, 2008
Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responsesWilliam H D Hallett, Erik Ames, Maite Álvarez, et al.
Oncoimmunology|September 26, 2015
Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cellsErik Ames, Robert J Canter, Steven K Grossenbacher, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 17, 2013
Murine natural killer cell licensing and regulation by T regulatory cells in viral responsesCan M Sungur, Yajarayma J Tang-Feldman, Erik Ames, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2007
Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibitionWilliam H D Hallett, Erik Ames, Milad Motarjemi, et al.
Cancers|January 17, 2019
Bortezomib Augments Natural Killer Cell Targeting of Stem-Like Tumor CellsJesus I Luna, Steven K Grossenbacher, Ian R Sturgill, et al.
Blood|April 19, 2011
Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHCIsabel Barao, Maite Alvarez, Erik Ames, et al.
Blood|July 11, 2014
Treatment of chronic graft-versus-host disease with bortezomibChien-Chun Steven Pai, Mingyi Chen, Annie Mirsoian, et al.
Pageof 3